ITCI - Intra-Cellular Company Value to Earnings Growth Ratio
Intra-Cellular Therapies (ITCI) is a distinguished leader in neuropharmaceuticals that has earned physician trust through its innovative drug Caplyta for the treatment of schizophrenia. The growth-weighted P/E on the GURU.Markets chart reflects evolving expectations, with the current parameter standing at 0.00. Drug development is accelerating via robotic cell monitoring, while a stable staff of neurobiologists is being augmented by the active hiring of commercial representatives.
Analytical breakdowns for Intra-Cellular Therapies (ITCI)
- stock price and consensus target price:
- market capitalization statistics:
- book capitalization information:
- issuer credit burden and liquidity indicators:
Debt to Capital Ratio Intra-Cellular Therapies|ITCI - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio intracellulartherapies.com|ITCI - Company Aggregate Debts|Debts to Book Value Intra-Cellular|ITCI - Company Long-Term Debt|Company Short-Term Debt Intra-Cellular Therapies|Quick Liquidity intracellulartherapies.com
- earnings and valuation multiples information:
ITCI - Net Income|Projected Future Earnings Intra-Cellular Therapies|ITCI - Price to Earnings Ratio|Future Price to Earnings intracellulartherapies.com|ITCI - PEG Multiple|EV/EBITDA Multiple Intra-Cellular|ITCI - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Intra-Cellular Therapies|ITCI - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months intracellulartherapies.com|ITCI - Net earnings per share growth this year|Projected earnings per share increase next year Intra-Cellular Therapies
General company analysis:ITCI - Intra-Cellular Therapies Inc.
The PEG ratio is used to find a balance between asset quality and valuation by comparing the current P/E multiple with earnings growth rates, identifying an undervalued business when the value is below one. In the case of Intra-Cellular Therapies (ITCI), strong pricing power and stable demand for the drug make the growth-adjusted P/E ratio a key indicator of the company's capitalization adequacy.
Competitors of Intra-Cellular Therapies
Biogen Inc - Growth-Adjusted P/E Ratio|Neurocrine Biosciences Inc - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio RGC (Regencell Corp)|AXSM - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio ACAD (acadia-pharm.com)|XENE: PEG Multiple|Viking Therapeutics Inc (VKTX) - PEG Multiple|Price/Earnings to Growth Multiple SUPN|CPRX - Price to Net Income Growth Ratio|PEG Multiple DNLI|Price/Earnings to Growth Multiple harmonybiosciences.com HRMY|PEG Multiple BHVN (Biohaven)|Amylyx Pharmaceuticals Inc (AMLX) - Price to Earnings Adjusted for Growth Rate|TRVI - Price/Earnings to Growth Ratio|PRAX: Price/Earnings to Growth Ratio|Anavex Life Sciences (AVXL) - Price/Earnings to Growth Ratio|CBLL (ceribell.com) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple PRTA|PEG Multiple Alector Therapeutics|Price/Earnings to Growth Ratio Annexon Inc. (ANNX)|Price/Earnings to Growth Ratio OMER (omeros.com)|PEG Multiple NGNE (Neurogene Inc.)|PEG Multiple acimmune.com ACIU|VYGR - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio NMRA (Neumora)|SCLX (Scilex Holding Co.) - Price/Earnings to Growth Multiple|Tevogen Bio Inc. - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple ACOG|CGTX (cogrx.com) - Company Value to Earnings Growth Ratio|PEG Multiple IKT|SAVA (Cassava Sciences Inc) - Growth-Adjusted Payback Ratio|PEG Multiple ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Price to Earnings Adjusted for Growth Rate|VTGN - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio OVID (Ovid Therapeutics Inc.)|ABOS: PEG Multiple|CervoMed, Inc. (CRVO) - PEG Multiple|Price/Earnings to Growth Ratio Alterity Therapeutics Ltd.|Clene Nanomedicine - Market Cap to Earnings and Growth Ratio|PEG Multiple PEPG|Growth-Adjusted Market Cap to Net Income jupiterneurosciences.com|PEG Multiple RLMD (Relmada Therapeutics, Inc.)|Annovis Bio Inc (ANVS) - Price to Earnings Adjusted for Growth Rate|GRCE - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Firefly Neuro AIFF|KLTO: PEG Multiple|NRSN - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple RVPH|MTVA (MetaVia, Inc.) - Company Value to Earnings Growth Ratio|PEG Multiple NRXS|Price/Earnings to Growth Multiple heliusmedical.com HSDT|PEG Multiple PASG (Passage Bio)|Growth-Adjusted Market Cap to Net Income Neuphoria Therapeutics, Inc. (NEUP)|NERV - Price/Earnings to Growth Ratio|ATHA (Athira Pharma Inc) - Growth-Adjusted P/E Ratio|ADXN: PEG Multiple|Price to Earnings Adjusted for Growth Rate Alzamend Neuro (ALZN)|Price/Earnings to Growth Multiple CYCN|PEG Multiple Protagenic|Price/Earnings to Growth Ratio Pasithea Therapeutics (KTTA)|CRGT (cortigent.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Avenue Therapeutics, Inc ATXI|BrainStorm Cell Therapeutics Inc. (BCLI) - Price to Earnings Adjusted for Growth Rate|Cara Therapeutics, Inc. - PEG Multiple|Growth-Adjusted Market Cap to Net Income chromocell.com CHRO|eliemtx.com (ELYM) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio LBPH|Price/Earnings to Growth Multiple MRNS|NKGN (NKGen Biotech Corp) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Ratio NeuroBo Pharmaceuticals (NRBO)|SAGE (sagerx.com) - Growth-Adjusted Payback Ratio|PEG Multiple SNPX (Synaptogenix)|PEG Multiple Trevena Inc. TRVN|VIGL: Price/Earnings to Growth Multiple|Price to Net Income Growth Ratio Anew Medical Inc. (WENA)|CERE: PEG Multiple
